Comparative Pharmacology of Cisatracurium (51W89), Atracurium, and Five Isomers in Cats

All experimental protocols used in these experiments were approved by our institutional Animal Care Use Committee and were in accordance with the United States Public Health Service, National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. These experiments were performed in purpose bred (Harlan Sprague Dawley, Indianapolis, Indiana) male cats, weighing 2.9-5.2 kg. All animals were anesthetized with a mixture of 7 mg/kg intraperitoneal pentobarbital sodium and 80 mg/kg intraperitoneal alpha-chloralose. Adequate levels of anesthesia were maintained with supplemental doses of alpha-chloralose (5-10 mg/kg) administered intravenously via a cannula in the femoral vein. The trachea was cannulated and the animals lungs were ventilated with room air via a Harvard Apparatus (South Natick, MA) respiration pump. Arterial blood pressure was measured from a cannula in the femoral artery connected to a Statham P23 transducer (Gould, Oxnard, CA). Heart rate was determined from the electrocardiogram (lead II) using a Grass Model 7P44 tachograph (Quincy, MA). The left hind limb was rigidly mounted and the tibialis tendon was isolated and attached to a Grass FT.03 force displacement transducer. After sectioning the sciatic nerve trunk at the hip, the peroneal nerve was mounted on platinum electrodes. Stimuli of 0.2-ms duration and at a supramaximal voltage were applied to the nerve at the rate of 0.15 Hz using a Grass S88 stimulator. Twitch tension in the tibialis anterior was recorded with a resting tension of 50 g. The right vagus nerve and the right sympathetic trunk were decentralized. Stimulating electrodes were placed on the distal stump of the vagus and on the preganglionic fibers of the sympathetic trunk. Ten-second trains of square waves at 20 Hz, 0.5-ms duration, and supramaximal voltage were applied to the nerve at 5-min intervals. The contractions of the right nictitating membrane at a resting tension of 5 g were recorded via a Grass FT.03 transducer. All recordings were made simultaneously for tibialis anterior twitch, electrocardiogram, arterial blood pressure, nictitating membrane contraction, and heart rate on a Grass Model 7 polygraph. Esophageal temperature was monitored with a Yellow Springs thermistor probe and core temperature was maintained between 37 degrees and 38 degrees C with radiant heat. All nerves and tendons were kept moist with mineral oil or mineral oil-soaked cotton. At the end of the experiments, cats were killed with intravenously administered saturated potassium chloride and/or pentobarbital sodium.

Onset of neuromuscular block was measured as the time from injection to maximal twitch depression, and total duration was measured as time from injection to return to 95% of control twitch height. Recovery times were measured for 5-95% and 25-75% return of twitch height. The dose-response curve for neuromuscular block was estimated by linear regression of probit values corresponding to the percentage depth of neuromuscular block. [4]Because of the strong similarity of the neuromuscular blocking effects, especially onset times and total durations observed with cisatracurium, atracurium, and vecuronium, additional comparative experiments were performed with cisatracurium, atracurium, and vecuronium. Pharmacodynamic trend analysis and statistical comparisons of neuromuscular ED values were made by analysis of variance with the Bonferroni correction for multiple comparisons with significance accepted at P < 0.05. [5].

Dose-response curves for inhibition of neuromuscular, vagal (parasympathetic), and sympathetic ganglionic function were determined for each animal. The dose-response curves were determined as follows: for neuromuscular blockade a dose-response curve (at least three doses) was constructed for each animal. The animal was allowed to remain stable between doses for 60 min after return of twitch baseline. Mean ED²⁵, ED⁵⁰, and ED⁹⁵values (doses that decreased the tibialis twitch height 25%, 50%, or 95%, respectively) were calculated from the individual log-probit dose-response curves. Parasympathetic dose-response curves were constructed in cumulative fashion using doses beginning with an approximate ED⁹⁵dose for neuromuscular block (NMB) and doubling the dose every 5 min up to approximately 50-100x the NMB ED⁹⁵. The vagus and sympathetic trunks were stimulated 2 min after each dose and the observed response was calculated as a percentage of the control response. The vagal ID⁵⁰values (doses that produced 50% inhibition of the response to vagus nerve stimulation) and the sympathetic ID²⁵values (doses that produced 25% inhibition of the response to sympathetic nerve stimulation) were determined from mean, log-probit dose-response curves.

A response suggestive of histamine release was sought after each single bolus dose of the compounds. The presence of a greater than 20% decrease in mean arterial pressure, a 20% increase in heart rate, as well as drug-induced contraction of the nictitating membrane were used as indicators suggestive of histamine release. The smallest dose resulting in observation of two of these indicators was considered the one causing the presumptive syndrome.

Plasma histamine concentrations were determined using a commercially available histamine enzyme immunoassay kit (Amac, Westbrook, ME). Five 3-ml arterial blood samples were obtained just before and 1, 2.5, 5, and 10 min after the bolus administration of 4,000 micro gram/kg cisatracurium or atracurium. Each sample was immediately placed in chilled polypropylene tubes containing 50 micro liter ethylenediaminetetraacetic acid and centrifuged within 5 min. The plasma was removed, kept chilled, and assayed immediately or stored at -80 degrees C until assayed.

Two different batches of the isomers (mesylate salts and besylate salts) and atracurium besylate were used in these experiments. The doses reported represent the weight of the parent bis-cation. Atracurium and the isomers were dissolved in cold, 0.9% NaCl with pH level of 3 and prepared fresh daily. The optical and geometric designations and the corresponding Burroughs Wellcome numbers of the six isomers are as follows: S,Trans-S',Trans (34W89), S,Cis-S'Trans (35W89), S,Cis-S',Cis (36W89), R,Trans-R',Trans (49W89), R,Cis-R',Trans (50W89), and R,Cis-R',Cis (51W89, Cisatracurium). The commercially available preparation of vecuronium was used for experiments performed with that agent.

Like atracurium, all six isomers produced dose-dependent inhibition of the evoked tibialis anterior twitch. The log-probit dose-response curves for atracurium and the six isomers were all parallel. The calculated (mean+/-SE) NMB doses are summarized in Table 1. The NMB ED⁹⁵values varied tenfold. Two "S-series" isomers were significantly less potent than atracurium. One was equipotent and the three "R-series" isomers were more potent than atracurium. All six isomers and atracurium were significantly less potent than vecuronium.

Also summarized in Table 1are the neuromuscular blocking effects observed for each agent at an approximate ED⁹⁵NMB dose. These data were obtained from responses observed in individual cats (n = 5 for each agent). In each case, the magnitude of inhibition of the tibialis twitch ranged from 95% to 99%. The onset times for the six isomers and atracurium (Figure 1and Table 1) varied inversely with NMB potency. Similarly, the total durations of action of the isomers and atracurium (Table 1) varied inversely with NMB potency (coefficient of correlation of best fit line = 0.94). With the exception of the relatively short duration of the S,Trans-S',Trans isomer, the total durations of the other five isomers were not significantly different from atracurium or vecuronium. The 5-95% and 25-75% recovery times of the six isomers indicate that, like atracurium, all undergo relatively rapid spontaneous recovery.

The neuromuscular blocking effects of cisatracurium, atracurium, and vecuronium observed after the administration of 1x and 4x the ED⁹⁵NMB doses and continuous infusions of doses that maintained 95-99% neuromuscular block for at least 60 min are shown in Figure 2. All three agents had similar onsets and total durations of action after the 1x or 4x the NMB ED⁹⁵doses. The recovery indexes for cisatracurium, observed after the bolus injections of the 1x and 4x ED⁹⁵NMB doses and after infusions were not significantly different from each other (Table 2) and indicate that, like atracurium, recovery is independent of dose or duration of neuromuscular block. In contrast, the 5-95%, and 25-75% recovery indexes observed after the 4x ED⁹⁵NMB dose of vecuronium were significantly longer than the corresponding indexes observed after the 1x ED⁹⁵NMB dose and the infusions.

The administration of 50 micro gram/kg intravenous neostigmine or 500 micro gram/kg intravenous edrophonium at 85% block of the tibialis anterior twitch produced by cisatracurium after an approximate ED⁹⁵NMB dose, significantly decreased the 5-95% times (range 43-65%) and 25-95% times (range 70-93%). Similar effects with the anticholinesterases were observed with all of the other isomers.

The relationships between the dose-response curves for neuromuscular block and inhibition of the responses to vagal and sympathetic nerve stimulations observed after large doses (530-5,300 micro gram/kg) of cisatracurium are shown in Figure 3. The ratios of the dose that produced 50% inhibition of the response to vagal nerve stimulation (vagal ID⁵⁰) to the NMB ED⁹⁵neuromuscular blocking dose and the ratios of the dose that produced 25% inhibition of the response of the nictitating membrane to sympathetic nerve stimulation (sympathetic ID²⁵) to the NMB ED⁹⁵, observed after the administration of each of the six isomers, as well as atracurium, or vecuronium, are summarized in Table 3. The vagal ID⁵⁰:NMB ED⁹⁵ratios varied 14-fold and the sympathetic ID²⁵:NMB⁹⁵varied 22-fold.

Doses of the six isomers and atracurium that produced cardiovascular effects after rapid bolus injection are summarized in Table 4. Atracurium and all of the isomers, except cisatracurium, produced cardiovascular effects (for typical response see Figure 4) over the same dose range in all the cats in each group. In these initial experiments, cisatracurium did not produce cardiovascular effects (for typical effects see Figure 4) at doses up to and including a dose equivalent to 85x the NMB ED⁹⁵. Plasma histamine concentrations were determined in a separate group of cats that received either cisatracurium or atracurium at intravenous bolus doses of 4,000 micro gram/kg. As summarized in Table 5, cisatracurium had no significant effect on plasma histamine concentrations; whereas, plasma histamine concentrations rapidly increased approximately 100-fold within the first minute after the administration of atracurium. No cardiovascular effects were observed after the administration of 4,000 micro gram/kg intravenous cisatracurium, but were observed in all cats after 4,000 micro gram/kg intravenous atracurium.

The results of this study indicate that all six isomers of atracurium had neuromuscular blocking activity. It is likely that all of the isomers contribute in a significant way to the NMB effects of atracurium, but possibly, because of the observed differences in potencies, onset times, and total durations, in an unequal way. None of the isomers produced muscle fasciculations or potentiation of twitch contraction, but all produced partial "tetanic fade" and "posttetanic potentiation" (data not presented) and were pharmacologically antagonized by the acetylcholinesterase inhibitors, neostigmine or edrophonium. Thus, the observed neuromuscular block had the characteristics of a nondepolarizing type of mechanism. The reason for the tenfold range of potencies is not known at this time, but it may be owing to a combination of enzymatic hydrolysis by plasma esterases in the cat and receptor affinity, and is most likely not owing to different rates of Hofmann elimination, the latter being a chemical reaction likely not influenced by stereochemical differences. The finding that the R-isomers were more potent than the corresponding S-isomers is in agreement with Stenlake et al. with the R and S isomer mixtures. The significant, inverse relationship between potency and onset time observed after the administration of equieffective neuromuscular blocking doses of the isomers and atracurium (Figure 1), support the hypothesis that nondepolarizing neuromuscular blocking agents of low potency have a more rapid onset of action than that seen with agents of high potency. [6-8]The significant, inverse relationship between duration and potency observed after the administration of approximate ED⁹⁵NMB blocking doses supports the suggestion that if a nondepolarizing equivalent of succinylcholine is discovered, it is likely to be a neuromuscular blocking agent of low potency. [3,8].

The total durations ranged from approximately 8 to 14 min with most of the isomers having a total duration similar to that of atracurium. The S,Trans-S',Trans isomer's total duration of 7.8 min+/-0.5 min is twice the total duration of an equieffective dose of succinylcholine (3.8 min+/-0.2 min) in our anesthetized cats. Tsui et al. reported that components of the Trans-Trans isomer groups may be hydrolyzed at different rates in human blood. [3]The differences in potency and duration observed in this study between the S,Trans-S',Trans and R,Trans-R',Trans isomers support his findings. Conversely, our results indicate that the S,Cis-S',Trans and the R,Cis-R',Trans isomers do not represent the proposed rapidly degraded components of the Cis-Trans isomeric group. It is likely that the other two isomers in the Cis-Trans isomeric group (R,Cis-S',Trans and S,Cis-R',Trans) have neuromuscular blocking profiles similar to the Cis-Trans isomers we tested; because, if hydrolysis occurs, it will occur at any one of the ester sites common to either the R,S, or meso isomers. The total duration of most of the isomers, especially the R-series, were very similar to both atracurium and vecuronium and, like atracurium and vecuronium, would be classified as intermediate-duration agents.

The effects of the isomers on the autonomic nervous system are typical of benzylisoquinolinium compounds. The only clinically available benzylisoquinolinium that will cause blockade of ganglionic transmission at doses equal to or only slightly greater than its ED⁹⁵neuromuscular blocking dose is d-tubocurarine. [9,10],* The dose ratios ([ID⁵⁰for vagal inhibition/NMB ED⁹⁵] and [ID²⁵for sympathetic ganglionic inhibition/NMB ED⁹⁵]) in cats are useful because they represent ratios that gauge the relative likelihood of occurrence of autonomic effects in humans under anesthesia. With the exception of the S,trans-S', trans isomer, all of the isomers had vagal ID sub 50 /NMB ED⁹⁵values greater than 10, with even higher sympathetic ID²⁵/NMB ED⁹⁵ratios. The low ratios observed with the S,trans-S',trans isomer are caused by its low NMB potency rather than an increased potency at autonomic receptors. The other five isomers, like atracurium, have a selective effect at the neuromuscular nicotinic receptor. These data are in agreement with many other comparisons in the cat of neuromuscular blocking properties versus autonomic effects that forecast a lack of cardiovascular effects in humans as a result of the autonomic effects of benzylisoquinolinium neuromuscular blockers.

Histamine release is thought to be the principal mechanism by which the newer benzylisoquinolinium neuromuscular blocking agents, e.g., atracurium and mivacurium, produce cardiovascular effects in humans.** In testing new drugs, investigators attempt to measure histamine release by several different methods, including histamine release from mast cell preparations, animal studies, and human studies. It is important to note that the amount of histamine in mast cells and the susceptibility to be released by chemical agents are both species and tissue dependent. We have chosen to study the cardiovascular effects of bolus intravenous injections of high doses of neuromuscular blocking agents in anesthetized cats as an initial index of histamine release because of our previous preclinical and clinical experiences with three benzylisoquinolinium neuromuscular blocking agents: atracurium, doxacurium, and mivacurium. Bolus intravenous administration of each of the five isomers of atracurium and atracurium itself produced decreases in arterial blood pressure, tachycardia in all of the 30 cats tested (n = 5 per compound), and in most cases, a small spontaneous contraction of the nictitating membrane. These responses were taken as indicative of the "histamine-release" syndrome. Cisatracurium, like vecuronium, did not produce this syndrome in any of the cats tested even though higher doses were administered (5,300 micro gram/kg, n = 4 and 2,600 micro gram/kg, n = 1). This finding was supported in a second study where it was observed that 4,000 micro gram/kg intravenous bolus injection of atracurium produced the typical histaminelike cardiovascular effects and increased the plasma histamine concentration more than a 100-fold, whereas, cisatracurium at an identical dose did not affect plasma histamine concentrations. Similar observations were observed in both anesthetized dogs (unpublished) and rhesus monkeys.*** Notably, in support of the findings with cisatracurium in cats, Lien et al. have reported that cisatracurium did not affect plasma histamine concentrations or produce important cardiovascular effects at doses up to and including eight times its human ED⁹⁵NMB dose in healthy patients undergoing elective surgical procedures. ^[11]To date, cisatracurium is the only benzylisoquinolinium neuromuscular blocking agent that does not produce cardiovascular effects or increase plasma histamine concentrations in experimental animals or humans at the doses tested.

These initial results identified cisatracurium, the R-R' optical isomer of the cis-cis configuration, which represents about 15% of the atracurium mixture, as a neuromuscular blocking agent that was 1.5 times more potent than atracurium, had neuromuscular blocking effects and lack of autonomic effects very similar to that of atracurium, yet was devoid of the cardiovascular and histamine-releasing properties of atracurium. Additional neuromuscular studies were subsequently performed for comparisons to the standard intermediate-duration neuromuscular blocking agents, atracurium and vecuronium. The absence of significant differences in the 5-95% and 25-75% recovery times after two different bolus doses or a 1-h infusion indicated that cisatracurium, like atracurium and unlike vecuronium, did not have cumulative effects in anesthetized cats. A lack of cumulative effects and a consistent pattern of recovery independent of the size of the bolus doses or the length of infusions of cisatracurium was recently reported in human adults by Belmont et al. [12]and in children by Meretoja et al. [13]These investigators also reported that, as in the cat, cisatracurium was more potent than atracurium, had a duration of action similar to that of atracurium, and its neuromuscular blocking effect was antagonized by neostigmine. The only difference in the neuromuscular blocking effects noted in both humans and cats was the significantly slower onset time of cisatracurium in comparison with equipotent doses of atracurium. The most likely explanation for this observation is the greater difference in neuromuscular potency between cisatracurium and atracurium observed in humans (3x) and cats (1.5x). In summary, the current study has identified cisatracurium as nondepolarizing neuromuscular blocking agent with overall neuromuscular blocking effects very similar to that of atracurium. Unlike atracurium and five other available component isomers in the atracurium mixture, cisatracurium does not produce cardiovascular effects or affect plasma histamine concentrations after the administration of large bolus doses. The observed greater potency and intermediate duration of action, consistent pattern of recovery and lack of cumulative effects, pharmacologic antagonism by anticholinesterases, as well as a lack of autonomic, cardiovascular and histaminelike effects have been confirmed in human studies. [11-13],**** The data indicate that cisatracurium represents an improved atracurium.

The authors thank Lois J. Cooper, for technical assistance with all animal experiments presented in this study; Dr. Eric Yung Sheng Wang, for the plasma histamine assays; and Gary L. LaMunion, Patricia F. Burns, and Judy A. McDuffie, for their assistance in data collection and manuscript preparation.

*Maehr RB, Belmont MR, Wray DL, Savarese JJ, Wastila WB: Autonomic and neuromuscular effects of mivacurium and its isomers in cats (abstract). ANESTHESIOLOGY 1991;75:A772.

**Basta SJ: Modulation of histamine release by neuromuscular blocking drugs. Curr Opin Anaesthesiol 1992;5:572-6.

***Belmont M, Beemer G, Bownes P, Wastila W, Savarese JJ: Comparative pharmacology of atracurium and one of its isomers, 51W89, in Rhesus monkeys (abstract). ANESTHESIOLOGY 1993;79:A947.

****Lepage JY, Malinovsky JM, Malinge M, Cozian A, Pinand M: 51W89: Dose response, neuromuscular blocking profile, and cardiovascular effects (abstract). ANESTHESIOLOGY 1993;79:A945.